News

18ICS finished with success

News 15 June, 2016
With about 80 participants from 15 countries the 18th International Cyclodextrin Symposium held on 18-21 May in Gainesville, USA was concluded with success.
more

Internet web site on cyclodextrins

News 2 May, 2016
Ars Technica, web site on technology news (founded in Cambridge, Massachussetts) has published a paper on the latest findings of cyclodextrins on atherosceloris with the title: “Sweet drug clears cholesterol, reverses heart disease—and was found by parents”.*
more

Breakthrough Therapy designation to HPBCD of Vtesse

News 1 February, 2016
Vtesse, Inc, a rare disease company, announced that FDA granted Breakthrough Therapy designation to VTS-270 (a proprietary form of HPBCD) for the treatment of children with Niemann-Pick Disease Type C (NPC).
more

SBEBCD for FDA-Approved Cannabinoid-based Medications

News 1 February, 2016
Virio Health, LLC announced that it has entered into exclusive license and supply agreement with Ligand Pharmaceuticals, Inc. for Captisol to be used for the development of cannabinoid-based medications.
more

Meridian Lab Announced Positive Outcome from Pre-NDA Meeting with FDA

News 1 February, 2016
Meridian Labs is a specialty pharmaceutical company focusing on the development of cancer treatments through formulation improvements.
more

Cyclodextrins on the Cover of Nature

News 1 February, 2016
Novel porous βCD polymer was prepared and used for rapid removal of organic micropollutants from water. The crosslinking agent, tetrafluoroterephthalonitrile ensures rigid structure and high porosity improving the availability of the CD rings within the structure.
more

FDA Approved Bridion

News 1 December, 2015
On 15 December 2015 FDA approved Bridion (Sugammadex) injection marketed by Merck Sharp & Dohme Corp. The safety and efficacy was proved in Phase 3 clinical trials involving 456 patients.
more

FDA Panel Recommended Approval of Sugammadex

News 1 December, 2015
After several rejections now an independent panel of US Food and Drug Administration recommended to approve sugammadex neuromuscular blockade antidote marketed as Bridion by Merck.
more

News from the Cyclodextrin Society of Japan

News 6 November, 2015
The annual prize of the society (2015 SCDJ award) was presented to Professor Kohzo ITO (Tokyo University) on his research on sliding gels.
more

Events

CycloLab’s Chapter

Events 4 November, 2016
With the title of “Potential of cyclodextrins in risk assessment and monitoring of organic contaminants” a chapter compiled by CycloLab together with Budapest University of Technology and Economy was published in Volume 3 (Site Assessment and Monitoring Tools) in a book series on Engineering Tools for Environmental Risk Management published by CRC.
more

CycloLab at EMN Meeting on Smart and Multifunctional Material - 2016

Events 1 August, 2016
The Energy, Material & Nanotechnology Meeting on Smart and Multifunctional Material was held on 23-26 August 2016 in Berlin. CycloLab presented an invited lecture (Milo Malanga) and a poster (Gábor Benkovics) in the session of "Optical and Biomedical Applications of Multifunctional Nanomaterials".
more

CycloLab contributed to the International Summer School

Events 15 July, 2016
The 3rd International Summer School organized by the Italian Cyclodextrin Society (Profs. F. Trotta and A. Mele) was finished with success.
more